PT Kalbe Farma Tbk.

Jakarta Stock Exchange KLBF.JK

PT Kalbe Farma Tbk. EBT Margin for the year ending December 31, 2023: 11.84%

PT Kalbe Farma Tbk. EBT Margin is 11.84% for the year ending December 31, 2023, a -23.15% change year over year. EBT Ratio (Earnings Before Tax Ratio) is the fraction of earnings before taxes to total revenue, indicating the company's profitability before the impact of tax expenses.
  • PT Kalbe Farma Tbk. EBT Margin for the year ending December 31, 2022 was 15.41%, a -2.32% change year over year.
  • PT Kalbe Farma Tbk. EBT Margin for the year ending December 31, 2021 was 15.78%, a 0.52% change year over year.
  • PT Kalbe Farma Tbk. EBT Margin for the year ending December 31, 2020 was 15.70%, a 4.40% change year over year.
  • PT Kalbe Farma Tbk. EBT Margin for the year ending December 31, 2019 was 15.03%, a -4.18% change year over year.
Key data
Date EBT Margin Net Income Margin EBITDA Margin EBIT Margin
Market news
Loading...
SV Wall Street
Jakarta Stock Exchange: KLBF.JK

PT Kalbe Farma Tbk.

CEO Mr. . Vidjongtius
IPO Date Dec. 15, 2003
Location Indonesia
Headquarters Gedung KALBE
Employees 12,924
Sector Health Care
Industries
Description

PT Kalbe Farma Tbk., together with its subsidiaries, develops, manufactures, and trades in pharmaceutical products in Indonesia. The company operates through four divisions: Prescription Pharmaceuticals, Consumer Health, Nutritionals, and Distribution and Logistic. It offers generic, branded, and licensed drugs, including Brainact, Cefspan, Mycoral, Cernevit, Cravit, Neuralgin, Broadced, Neurotam, Hemapo, and CPG that are distributed to hospitals, pharmacies, and drug stores. The company also provides over-the-counter drugs; energy drinks, ready-to-drink products, supplements, and other preventive products; and nutritional products for infants, toddlers, children, teenagers, adults, pregnant and lactating women, and elders, as well as for consumers with special medical needs. In addition, it offers contract services, including clinical study management, bioavailability/bioequivalence studies, and contract analysis to pharmaceutical companies; and animal health products, as well as operates Mitrasana Clinics, a health care service. Further, the company provides health screening services; operates as an agent and representative for biotechnology products; distributes consumer products, medical equipment, cosmetics, and other trading products; and trades in medical and laboratory equipment and supplies, raw materials for pharmaceutical products, and consumable products for hemodialysis therapy, as well as offers advertising services. PT Kalbe Farma Tbk. was incorporated in 1966 and is headquartered in Jakarta, Indonesia.

Similar companies

INDF.JK

PT Indofood Sukses Makmur Tbk

USD 0.47

2.32%

SMGR.JK

PT Semen Indonesia (Persero) Tbk

USD 0.18

-0.06%

UNVR.JK

PT Unilever Indonesia Tbk

USD 0.10

-1.28%

ASII.JK

PT Astra International Tbk

USD 0.30

1.02%

UNTR.JK

PT United Tractors Tbk

USD 1.56

0.24%

StockViz Staff

January 31, 2025

Any question? Send us an email